Alnawaz Rehemtulla

Title: Alnawaz Rehemtulla: Innovator in Chimeric Antigen Receptors

Introduction

Alnawaz Rehemtulla is a prominent inventor based in Plymouth, MI (US). He has made significant contributions to the field of biotechnology, particularly in the development of chimeric antigen receptors (CAR) for cancer treatment. With a total of 9 patents, his work has the potential to revolutionize cancer therapies.

Latest Patents

One of his latest patents focuses on chimeric antigen receptors targeting abnormal glycobiology. The disclosure provides a CAR polypeptide that includes an antigen binding domain with an extracellular lectin. This lectin specifically binds to glycoproteins expressed on the surface of target cells. Additionally, the patent includes engineered lymphocytes that express the CAR polypeptide, a nucleic acid molecule encoding the CAR polypeptide, and methods for treating cancer.

Career Highlights

Throughout his career, Alnawaz has worked with notable institutions such as the University of Michigan and Neoplasia Press, Inc. His innovative research has garnered attention and respect within the scientific community.

Collaborations

Alnawaz has collaborated with esteemed colleagues, including Brian Dale Ross and Thomas L Chenevert. These partnerships have further enhanced his research and contributions to the field.

Conclusion

Alnawaz Rehemtulla's work in developing chimeric antigen receptors represents a significant advancement in cancer treatment. His innovative approach and dedication to research continue to inspire future developments in biotechnology.